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1. Introduction
In nuclear cardiology, myocardial perfusion imaging has been widely and thoroughly inves‐
tigated and used in various heart diseases, especially in ischemic heart diseases. However,
beyond perfusion imaging, myocardial fatty acid metabolic imaging may yield valuable in‐
sight into the pathologic process of various heart diseases including ischemic heart diseases,
cardiomyopathy, and diabetic heart etc [1, 2].
To run the contractile machinery and ion pumps to maintain rhythmic beating and integrity
of the myocardium, the healthy heart derives its energy from a variety of oxidizable sub‐
strates such as fatty acids, glucose, lactate, amino acids etc. Approximately two-thirds or
more of the total energy produced by myocardium is derived from fatty acid oxidation and
the most of the remaining energy is covered by the glucose metabolism. Both fatty acid and
glucose are catabolized to acetyl-COA through beta-oxidation and glycolysis and the metab‐
olite is oxidized in the tricarboxylic acid (TCA) cycle (Fig 1). To respond the constantly
changing environmental conditions and energy demands, the heart maintains the balance
between its energetic supply and demands by shifting fluxes through existing various meta‐
bolic pathways. Short-term modulation of substrate switching is based on an effective inter‐
play between various substrates, with metabolism of one substrate automatically
suppressing the pathway of another substrate via rapid enzymatic changes. In the postpran‐
dial and under resting conditions, long-chain fatty acids are the predominant energy sub‐
strate for adult heart. On the other hand, during exercise or stress, predominant energy
source shifts to carbohydrate [3] because the efficiency of glucose as substrate exceeds the
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efficiency of fatty acids as substrate by as much as 40% [4]. In ischemia, oxidative metabo‐
lism of free fatty acid is decreased because β-oxidation of fatty acid in mitochondria requires
a large amount of oxygen, and glucose becomes the preferred substrate for anaerobic glycol‐
ysis that requires less oxygen consumption [5,6]. This metabolic switch from predominat fat‐
ty acid use to predominant glucose use seems crucial in preserving myocardial viability.
(Fig 2) Therefore, different imaging tracers that permit direct assessment of myocardial me‐
tabolism are desired to evaluate the pathophysiological changes in various heart disease.
Current available tracers for metabolic imaging are several fatty acid tracers, 18F-FDG for the
evaluation of glucose metabolism, and 11C-acetate for the assessment of oxygen consump‐
tion. Of these tracers, only 123I-labeled fatty acid tracers are currently available for SPECT
imaging. In this chapter, basic characteristics and clinical value of 123I-labeld fatty acid
agents, especially β-methyl-p-123I-iodophenyl-pentadecanoic acid (BMIPP) follows.
Figure 1. Schematic presentation of substrates metabolism in myocardium. ADP = adenosine diphosphate, AMP = ad‐
enosine monophosphate, ATP = adenosine triphosphate, BMIPP = β-methyl-iodophenyl-pentadecanoic acid, CoA =
coenzyme A, FFA = free fatty acid, PDH = pyruvate dehydrogenase, TCA = tricarboxylic acid, TG = triglyceride
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Figure 2. Relation between myocardial perfusion and fatty acid and glucose metabolism.
When myocardial  perfusion decreases,  fatty  acid metabolism can not  be maintained be‐
cause β-oxidation of  fatty acid in mitochondria requires a  large amount of  oxygen,  and
glucose becomes the preferred substrate for anaerobic glycolysis that requires less oxygen
consumption.  Therefore,  the  decrease  in  tracer  uptake  for  fatty  acid  substrate  analogue
such as  BMIPP becomes  more  prominent  than the  decrease  of  perfusion tracer.  On the
contrary,  anaerobic glucose metabolism relatively increases,  presenting increased or pre‐
served FDG uptake in the area with reduced perfusion. When myocardial perfusion de‐
creases  further,  glucose  anaerobic  metabolism  also  declines  finally  and  myocardial
viability will be lost eventually.
2. Myocardial fatty acid metabolism
Although the primary sources of energy are lactate and glucose for fetal heart, fatty acids
comprise 60% to 80% of the energy source in adult heart to run the contractile machinery
and ion pumps to maintain rhythmic beating and integrity of the myocardium [7].
Due to hydrophobic nature of  fatty acids,  they are delivered to the heart  by binding to
plasma  albumin  or  lipoproteins.  After  dissociating  from  albumin  or  lipoprotein,  fatty
acids can pass through the sarcolemmal membrane by diffusion or a facilitated transport
mechanism. The fatty  acid translocase CD36 was suggested that  it  accounts  for  the key
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uptake mechanism of  long-chain fatty  acid through the  analysis  of  minority  of  patients
with  absent  uptake  of  123I-BMIPP  (15-(p-iodophenyl)-3(R,  S)-methylpentadecanoic  acid)
even without significant cardiac abnormality [8,9] The patients with deficient myocardial
uptake of BMIPP has been proved to correspond to the patients with type I  CD36 defi‐
ciency (neither platelets nor monocytes expresse CD36) [10-12] and biopsy specimen from
the patients  with absent  myocardial  BMIPP uptake and type I  CD36 deficiency demon‐
strated no expression of CD36 on the myocardial capillary endothelial cells [13]. These pa‐
tients without BMIPP cardiac uptake showed compensatory increased FDG uptake [14,15]
and  several  gene  abnormalities  related  to  CD36  deficiency  have  been  reported  [16,17].
Based on these clinical data and other animal experiments, it has been proved that CD36
plays a crucial role in fatty acid transport into the cells [18].
Once the fatty acid is taken up by the myocyte, it undergoes adenosine triphosphate (ATP)
dependent conversion to acyl-CoAs and are consequently trapped inside the cell. Then the
acyl-CoAs are taken up by mithochondria via an acyl carnitine carrier system and is rapidly
catabolized by β-oxidation into 2-carbon fragments, acetyl-CoAs, which enter the TCA cycle
for further oxidation to become water and carbon dioxide. (Fig 1) The half-life of β-oxidation
is fast and in the order of minutes, but is dependent on the adequate oxygen availability.
The remainder of the total fatty acid entering the myocyte is incorporated into the lipid pool,
mainly in the form of triglycerides and phospholipids, or into myocardial structural lipids
and presents in the myocardium for a long time. Turnover in the lipid pool is much slower
with the half-life of the order of hours.
3. Tracers for fatty acid imaging for SPECT (Fig 3)
In mid 1970’s, several iodinated long chain fatty acids were developed by introducing ra‐
dioiodine to the terminal position of fatty acids without altering extraction efficiency com‐
pared  with  the  natural  compound  [19-21].  These  straight  chain  fatty  acids,  123I-
hexadecanoic  acid  (IHXA)  and  123I  -heptadecanoic  acid  (IHDA)  were  proved  to  be  an
indicator of myocardial perfusion in canine model and human [20,21]. After rapid initial
myocardial  extraction these traces showed biexponential  clearance similar to that of 11C-
palmitate with rapid and slow components, those were thought to represent β-oxidation
of fatty acids and fatty acids storage in lipid pool, respectively. However, a canine study
suggested that washout rate of radioactivity from the heart reflected the back diffusion of
deiodinated free iodine not by β-oxidation [20]. A clinical study with IHDA demonstrated
high image quality early after injection but it deteriorated rapidly because of rapid reduc‐
tion of myocardial counts and increase in background counts by deiodinated radioiodine
[23].  Accordingly, these characteristics of the tracers make IHDA and IHXA unattractive
for clinical use, especially for SPECT study.
To overcome the problem of these alkyl fatty acids, the phenyl fatty acid was developed by
attaching iodide to the para position of phenyl ring (IPPA) [24]. Because this agent demon‐
strates high myocardial uptake without essential release of free radioiodide into circulation,
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the image quality is excellent. Animal experiment demonstrated that the IPPA accumulated
rapidly to myocardium followed by a two-component tracer clearance similar to 14C-palmi‐
tate, permitting estimation of metabolic rate [25]. The uptake of IPPA during exercise is re‐
lated to myocardial perfusion and its catabolism follows the usual metabolic pathway for β-
oxidation [26]. Through β-oxidation IPPA is metabolized to iodobenzoic acid and its
metabolite iodohippurate, and these are rapidly excreted from the kidneys with the iodine
still attached, resulting in high image quality with low background by preventing the build‐
up of free radioiodide [27]. Coronary occlusion and reperfusion blunted the uptake of IPPA
and prolonged the clearance, but permanent coronary occlusion decreased the uptake signif‐
icantly and accelerated the clearance, indicating that the IPPA can be used to localize the
area of myocardial ischemia and infarction [28]. However, still relatively fast rate of metabo‐
lism and clearance of IPPA precludes the clinical SPECT imaging, even in a rotating multi-
detector SPECT system. For initial IPPA uptake imaging, acquisition time should be
shortened to prevent progressive undersampling due to rapid count decrease from the myo‐
cardium, resulting in the deterioration of image quality, and dynamic SPECT study may be
necessary for kinetic analysis of β-oxidation. For this purpose, dynamic SPECT with cadmi‐
um zinc-telluride (CZT) multi-detector might be the choice of data acquisition and analysis
because of its high sensitivity [29].
Figure 3. Iodinated fatty acids analogues for SPECT. BMIPP = β-methyl-iodophenyl pentadecanoic acid, DMIPP = di‐
methyl-iodophenyl pentadecanoic acid, IHDA = 123I-heptadecanoic acid, IHXA =123I-hexadecanoic acid, IPPA = iodo‐
phenyl pentadecanoic acid,
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Accordingly, a new fatty acid tracer with more prolonged cardiac retention has been devel‐
oped to improve quantitative image quality. For this purpose methyl branching was intro‐
duced at β-carbon position to slow myocardial clearance by inhibiting β-oxidation. Tow
forms of iodine labeled modified fatty acids, 15-(p-iodophenyl)3-R, S-methylpentadecanoic
acid (BMIPP) and 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid (DMIPP), has been de‐
veloped [30,31]. In fasted rats, myocardial half-time of BMIPP and DMIPP are far longer, at
30-45 min and 6-7 hr, respectively, than that of IPPA (5-10 min) [31]. In human, DMIPP
showed higher liver uptake than that of BMIPP (heart/liver ratio was 0.39 ± 0.05 and 1.00 ±
0.12, respectively: p<0.001), suggesting that BMIPP is more favorable cardiac SPECT agent
[32]. Especially in Japan and some European countries, BMIPP has since been widely stud‐
ied to investigate the clinical significance and basic properties. In Japan, 123I-BMIPP has been
used in daily clinical practice for nearly 2 decades since 1993.
4. Myocardial kinetic of 123I-BMIPP (Fig 4)
After intravenous injection of 123I-BMIPP, the tracer is delivered to myocardium depending
on the regional flow and transported into myocardial cells via fatty acid translocase/CD36
involvement [10,11,13,16-18]. Once BMIPP is taken up by the myocyte, it will either back-
diffuse to the plasma, accumulate in the lipid pool or undergo limited alpha and beta oxida‐
tion. Most of the BMIPP in the cytoplasm undergoes ATP dependent conversion to BMIPP-
CoA and incorporated into triglyceride pool [31,33]. Canine study demonstrated that high
first pass extraction (74%) within 30 sec of intracoronary BMIPP infusion, followed by a
small fraction of washout (8.7% of infused BMIPP) for the next 30 min [34]. The washed out
radioactiviy consist of backdiffused BMIPP (24% of all washed out radioactivity), α oxida‐
tion metabolite (27%), intermediate metabolites (33%), and full metabolite (16%), suggesting
only small amount of BMIPP-CoA transported into mitochondria is metabolized by α oxida‐
tion (because first β oxidation is blocked by β-methyl branching), followed by β oxidation.
The high uptake and low washout of the tracer indicates that BMIPP can be substantially
considered as a metabolically trapped tracer like FDG.
Thirty minutes coronary occlusion and reperfusion was found to increase early back dif‐
fusion of nonmetabolized BMIPP from 25.1% to 34.7%, and in mild ischemia with 10 mi‐
nutes occlusion,  back diffusion of  BMIPP was closely correlated with lactate production
(marker of ischemic severity) [35]. Pharmacological intervention with etomoxir, one of the
carnitine  palmotoyltransferase  I  inhibitor  that  inhibits  the  transport  of  long chain lipids
into the mitochondria, enhanced early washout of radioactivity until 8 minutes after injec‐
tion due to increased back diffusion of BMIPP [36]. Dynamic SPECT in patients with coro‐
nary  artery  disease  demonstrated  that  the  BMIPP  washout  was  observed  early  after
BMIPP injection (2-6 min after injection) in the segments with stress induced thallium de‐
fects but not in the segments with normal thallium uptake and fixed thallium defects [37].
In patients with acute coronary syndrome, early dynamic BMIPP SPECT showed similar
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BMIPP and thallium uptake, whereas conventional BMIPP images at 30 min demonstrat‐
ed the discordant BMIPP uptake less than thallium [38]. These findings suggest that, in is‐
chemic myocardium, initial myocardial distribution of BMIPP may represent blood flow,
followed by back diffusion of free BMIPP which is not incorporated into triglyceride pool
after conversion to BMIPP-CoA, resulting in discordant BMIPP uptake less than thallium
on static images obtained 20-30 min after BMIPP injection.
In the first step of the common pathway of fatty acid metabolism, BMIPP also underwent
ATP dependent conversion to BMIPP-CoA. Once BMIPP-CoA is synthesized, it is hardly
back-diffused out of the cell and is retained within it [39,40]. Therefore, BMIPP myocardial
retention may relate to the ATP level of the cells. Both in mouse myocardium treated with
an electron transport uncoupler, dinitrophenol, which reduced intracellular ATP level with‐
out affecting acyl-CoA synthetase activity or CoA level, and in acutely damaged canine my‐
ocardium by coronary occlusion and reperfusion, BMIPP uptake was found to correlate
with the tissue ATP levels [41,42]. Therefore, myocardial BMIPP uptake most likely reflects
activation of BMIPP by CoA and indirectly reflects cellular ATP production resulting from
fatty acid metabolism.
During acute phase of ischemia, reduced availability of oxygen suppresses β-oxidation and
increases the proportion of fatty acid in the triglyceride pool. At this moment BMIPP may
enter into this enlarged triglyceride pool. Accordingly, BMIPP uptake may possibly be in‐
creased in acute ischemia. Canine experiments with occlusion and reperfusion model
showed higher BMIPP uptake than thallium (reverse mismatch) which is an opposite find‐
ing observed in clinical studies [43,44]. However, BMIPP uptake may change as a function
of time after ischemia. A rat study with 20 min coronary occlusion and reperfusion demon‐
strated higher BMIPP uptake than thallium at 1 day after reperfusion but showed similar to
or lower than thallium uptake at 5 day after reperfusion [45]. Another rat study with 20 min
coronary occlusion and reperfusion revealed that increased BMIPP uptake in area at risk at
20 min and 1 day after reperfusion, followed by reduction of uptake at 3 to 7 days, though,
recovered to normal level at 30 days after reperfusion [46]. By contrast, thallium uptake did
not change throughout the 30 days observation period. As a result, higher BMIPP uptake
than thallium in acute phase was inverted in subacute phase (discordant or mismatch
BMIPP uptake less than thallium) and recovered to the similar uptake to that of thallium.
After a transient ischemic insult, recovery of myocardial perfusion, metabolism and function
may be temporally different. Although, delayed recovery of function after transient ische‐
mia is well documented in the experimental and clinical setting as stunned myocardium, de‐
layed recovery of regional metabolism or metabolic stunning which provide imprint prior
ischemic event has been recognized recently. This delayed recovery of metabolism after
quick recovery of perfusion provides a concept of ischemic memory imaging [47-50]. Thus
BMIPP imaging during or after an episode of myocardial ischemia might provide crucial in‐
sights into pathophysiology of coronary artery disease over perfusion imaging.
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Figure 4. Schematic presentation of 123I-BMIPP metabolism in myocardium. Abbreviations: see Figure 1.
5. 123I-BMIPP imaging in ischemic heart diseases
5.1. Acute myocardial infarction
Discrepant  BMIPP uptake less  than thallium has  been reported initially  in  17  out  of  28
patients  with acute  myocardial  infarction.  Such discordant  BMIPP uptake was observed
more often in areas of acute than chronic phase of myocardial infarction (59% at <4 week
versus  31% at  >4  week after  onset),  and more  often  in  areas  supplied  with  revascular‐
ized than non-revascularized arteries (74% versus 28%, respectively). In addition, region‐
al  wall  motion  was  more  severely  impaired  in  such  perfusion-metabolic  mismatching
area [51]. In patients with acute myocardial infarction, BMIPP and 99mTc-MIBI SPECT at 4
to 10 days after thrombolysis demonstrated that the segments with more reduced BMIPP
uptake  than  MIBI  uptake  (mismatching)  showed either  normal  wall  motion  or  demon‐
strated inotropic reserve during dobutamine stimulation [52]. In addition, several studies
had demonstrated that  areas  of  discordant  BMIPP uptake less  than perfusion tracers  in
acute  or  subacute  stages  of  myocardial  infarction  showed improvement  of  wall  motion
abnormality  on  the  subsequent  follow-up  periods  [47,53-59].  These  findings  suggested
that  mismatch  or  discordant  BMIPP  uptake  less  than  perfusion  is  indicative  of  jeopar‐
dized but viable myocardium and may correspond to stunned myocardium where func‐
tional  abnormality  is  prolonged  in  association  with  sustained  metabolic  abnormalities
(metabolically  stunned  myocardium)  after  perfusion  recovery  by  successful  reperfusion
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procedures.  Accordingly,  the  finding  of  mismatched  BMIPP  uptake  less  than  perfusion
tracers may be a predictor of functional recovery in acute myocardial infarction. For the
evaluation  of  area  at  risk  in  acute  myocardial  infarction,  BMIPP  imaging  in  subacute
phase is valuable. BMIPP defect size in subacute phase of myocardial infarction correlat‐
ed  well  with  the  risk  area  revealed  by  contrast  ventriculography  or  echocardiography
[47,60],  and the area with BMIPP reduction 1 week after the onset of myocardial infarc‐
tion corresponded well to the area with perfusion defect which was demonstrated before
revascularization therapy at admission [61].  These observations holds the concept of “is‐
chemic  memory imaging” because BMIPP imaging obtained in subacute phase of  myocar‐
dial infarction reflects prior ischemic damage or metabolically stunned myocardium even
after  the  restoration  of  perfusion  abnormality  [47-49].  Therefore,  BMIPP  imaging  may
contribute to improving the detection of culprit lesion of the small amount of acute myo‐
cardial infarction. In patients with non ST elevated and non serum creatinine kinase-MB
elevated  but  increased  cTnT  level,  BMIPP  SPECT  at  subacute  phase  can  detect  culprit
coronary lesions more sensitively than thallium [62].
Mismatched uptake of BMIPP less than thallium is not also an uncommon finding in chronic
phase of myocardial infarction. In 26 patients with prior myocardial infarction (>4 week af‐
ter onset) without revascularization therapy, resting BMIPP and exercise-redistribution thal‐
lium scintigraphies were studied. Sixty-seven % of the segments with discordant BMIPP
uptake less than redistribution thallium showed reversible thallium defects, 21% showed
fixed thallium defects and 12% showed normal thallium uptake, indicating that the myocar‐
dium with discordant BMIPP uptake less than redistribution thallium uptake were mostly
exposed to stress induced ischemia [37]. In subacute to chronic phase of infraction (>2 week
after onset), similar findings were reported, with most of the mismatched segments (22/27)
is associated with reversible thallium defect [63].
5.2. Acute coronary syndrome and unstable angina pectoris
Because oxygen extraction by the myocardium is nearly complete, reduction of coronary
flow against the myocardial oxygen demand evoke the metabolic switch from fatty acid
oxidation to anaerobic glucose metabolism. Thus the BMIPP uptake might be suppressed
in ischemia.  In  a  study of  111 consecutive patients  with acute  chest  pain without  myo‐
cardial infarction, BMIPP SPECT at 2 days after the onset of chest pain showed regional
abnormality in 74% of coronary abnormalities,  while only 38% showed perfusion abnor‐
mality  demonstrated by tetrofosmin within 24  hr  after  the  onset  of  chest  pain [64].  Re‐
cently,  multicenter  trial  to  evaluate  the  performance of  BMIPP to  detect  acute  coronary
syndromes in  emergency department  patients  with chest  pain was conducted in  a  total
of  507 patients  without  history of  prior  myocardial  infarction [65].  BMIPP imaging was
performed within 30 hours of symptom cessation. Sensitivity of detecting acute coronary
syndrome increased from 43% in clinical diagnosis to 73% in BMIPP imaging alone. Both
negative and positive predictive values of a clinical diagnosis alone increased significant‐
ly  when  combined  BMIPP  imaging  from  62%  to  83%  and  41%  to  58%,  respectively.
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These findings indicates that BMIPP imaging can detect prolonged metabolic abnormali‐
ty or stunning in patients with acute chest pain up to 2 days after cessation of symptom.
In  patients  with  unstable  angina,  discordant  BMIPP uptake  less  than  thallium has  also
been observed frequently [66-69]. In patients with unstable angina without prior myocar‐
dial infarction, comparison of BMIPP image and stress thallium scan performed after sta‐
bilization  of  their  condition  demonstrated  that  BMIPP  decrease  was  associated  with
stress perfusion abnormality in 44 of 57 (77%) segments and degree of BMIPP reduction
correlated with the degree of perfusion abnormality at stress,  degree of wall motion ab‐
normality, and severity of coronary artery stenosis [66]. In another study in patients with
unstable  angina  after  medication  and  elimination  of  chest  pain  disclosed  that  patients
with abnormal BMIPP uptake had more severe coronary artery stenosis and more collat‐
eral  opacification  than  patients  without  BMIPP  abnormality.  In  addition,  revasculariza‐
tion was performed in 82% of patients with abnormal BMIPP images, while in only 22%
of patients  with normal  BMIPP images,  accordingly,  BMIPP imaging may be helpful  in
decision-making regarding interventional  treatment [68].  These findings indicate that  re‐
duced BMIPP uptake in patients with unstable angina may represent persistent metabol‐
ic  abnormality  reflecting  prior  severe  ischemia  or  repetitive  ischemic  insults,  thus  the
concept  of  ischemic  memory  imaging  could  be  extended  and  applied  to  these  patients
population. In other words, BMIPP imaging could extend time window for detecting pre‐
vious ischemic event after the resolution of perfusion abnormality.
5.3. Chronic stable coronary artery disease
In  chronic  stable  coronary artery  disease  even without  history of  myocardial  infarction,
discordant BMIPP uptake less than perfusion tracer is also a common finding. Compari‐
son of BMIPP and stress-reinjection thallium SPECT in 45 patients with chronic coronary
artery disease demonstrated that most of the segments (118/124) with discordant BMIPP
uptake less than reinjection-thallium were associated with demand ischemia indicated by
reversible thallium defects [70]. When reversible thallium defects were analyzed, approxi‐
mately  half  of  the  segments  evidenced  discordant  BMIPP  uptake  less  than  reinjection
thallium.  On  the  other  hand,  around  80%  of  the  segments  with  fixed  thallium  defects
demonstrated  concordant  reduction  of  both  tracers,  suggesting  myocardium  with  re‐
duced or poor viability has metabolic abnormality similar to the degree of resting perfu‐
sion  abnormality.  When  reversible  thallium  defects  were  analyzed  with  respect  to  the
evidence of discordant BMIPP uptake less than thallium and regional wall motion abnor‐
mality, wall motion was more severely impaired in the segments with discordant BMIPP
uptake less than thallium than those without such discordance in both subset of patients
with and without old myocardial infarction. However, severity of coronary artery steno‐
sis  was similar  in the vascular  teritory with discordant BMIPP uptake less  than reinjec‐
tion  thallium  and  those  without  such  discordance.  Comparison  of  BMIPP  and  stress-
redistribution-reinjection  thallium  imaging  in  55  patients  with  stable  coronary  artery
disease revealed that discordant BMIPP uptake less than thallium was observed in only
37% of the segments with thallium redistribution after exercise, on the contrary, such dis‐
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cordance was observed in 82% of the segments with no redistribution but new fill-in af‐
ter thallium reinjection [71].  In addition,  such discordance was observed in only 19% of
the  segments  with  fixed  defects.  Previous  studies  with  stress-redistribution-reinjection
thallium demonstrated that the myocardium with new fill-in after thallium reinjection is
characterized as severely ischemic but viable myocardium with frequent wall motion ab‐
normalities  that  may recover  after  revascularization [72,73].  Accordingly,  these  observa‐
tion may indicate  that  discordant  BMIPP uptake less  than thallium is  suggestive  of  the
myocardium jeopardized by more severe ischemia.
The concept of ischemic memory imaging of BMIPP has been tested in 32 patients with exer‐
cise-induced ischemia on thallium SPECT. BMIPP imaging at rest within 30 hrs of ischemia,
which was induced and confirmed by exercise thallium SPECT, revealed reduction of
BMIPP uptake corresponding to the ischemic area detected by stress thallium study in more
than 90 % of patients [50]. Therefore, the authors concluded that BMIPP can identify sus‐
tained metabolic abnormality as a ischemic memory imaging at least until 30 hrs after stress
induced ischemic episodes. This finding was complemented by the studies assessing glucose
metabolism in patients undergoing exercise testing using FDG. Those have shown that a
metabolic switch from fatty acid to glucose use occurs promptly when myocardial ischemia
is induced during exercise and this metabolic switch to glucose may persist for 24hours, de‐
spite restoration of blood flow at rest [74,75].
Accumulated data in patients with chronic ischemic heart disease in Japan, however, dem‐
onstrated that reduced BMIPP uptake was frequently observed independent of prior radio‐
nuclide and ECG stress tests but related to severe ischemia and wall motion abnormality,
raise the possibility that BMIPP reduction reflects the substrate shift from fatty acid to glu‐
cose as a results of repeated myocardial ischemia rather than reflecting the single episode of
metabolic stunning. Myocardium exposed to repetitive ischemia or stunning is subsequently
adapted metabolically (metabolic remodeling) into chronic ischemic myocardium, so called
hibernation [76-78]. In hibernating myocardium, energy substrate is shifted from fatty acid
to glucose, contractility is impaired but with recruitable inotropic reserve, and myocardial
flow reserve is severely impaired. In relation to this issue, relationship between BMIPP up‐
take and absolute myocardial blood flow by PET was investigated in patients with chronic
stable angina without previous myocardial infarction. The results demonstrated that rest
myocardial blood flow was preserved independent of BMIPP uptake. However, hyperemic
myocardial blood flow was decreased in the area with reduced BMIPP uptake, resulting in
the severity of impaired myocardial flow reserve correlated to the reduction of BMIPP up‐
take [79]. Thus, reduced BMIPP uptake implies impaired myocardial flow reserve and may
reflects adaptive substrate shifts or metabolic remodeling in hibernating myocardium. Rep‐
resentative case with stable angina pectoris who underwent BMIPP and thallium SPECT be‐
fore and after coronary intervention (Fig 5).
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Figure 5. Short axis and horizontal long axis slices of 201Tl, 123I- BMIPP and gated blood pool images. The patient with
angina pectoris underwent thallium and BMIPP SPECT. Discordant BMIPP uptake less than thallium in antero-lateral
wall was observed (arrows). Gated blood pool scintigraphy demonstrated mild hypokinesis in antero-lateral wall.
Stroke volume image showed reduced stroke volume in anterolateral wall (arrow). Coronary angiography showed se‐
vere stenosis of the first diagonal brunch of the left anterior descending coronary artery. Coronary angioplasty was
successfully performed and BMIPP uptake and wall motion abnormality improved 8 month later. The discordant
BMIPP uptake less than thallium depicted the dysfunctional but viable myocardium or hibernating myocardium in an‐
terolateral wall. ED = end-diastolic, ES = end-systolic, PTCA = percutaneous transluminal coronary angioplasty, SV =
stroke volume
5.4. Detection of coronary artery disease
Meta-analysis for the assessment of diagnostic accuracy of BMIPP imaging for the detection
of coronary artery disease was conducted with 7 studies between 1995 and 2004 [80]. A total
of 528 patients with a high prevalence of coronary artery disease who underwent both
BMIPP imaging and coronary angiography were analyzed using a random-effects model.
The overall sensitivity and specificity were 78% (95% confidence interval, 73% to 81%) and
84% (95% confidence interval, 77% to 89%). The summary receiver operating characteristic
curve analysis showed that the area under the curve was 0.91 (SE, 0.020), and the Q* index
was 0.84 (SE, 0.022), indicating excellent diagnostic accuracy. This diagnostic performance is
comparable with stress myocardial perfusion SPECT reported by meta-analysis; a sensitivity
and specificity of 88% and 73%, respectively [81]. Thus, stress SPECT imaging is a more sen‐
sitive test, whereas BMIPP imaging is a more specific test. Unlike stress myocardial perfu‐
sion imaging, BMIPP imaging is obtained without the use of exercise or pharmacologic
agents. Therefore, BMIPP imaging at rest may be an alternative imaging modality for those
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who are unable to perform adequate exercise testing or pharmacologic stress myocardial
perfusion imaging, such as those presenting with acute chest pain and patients with end
stage renal disease with hemodialysis.
5.5. Myocardial viability assessment and prediction of functional recovery
Improvement of  regional  or global  systolic  function can be achieved if  revascularization
of viable myocardium is successfully performed. Therefore,  assessment of residual myo‐
cardial  viability  in  the  setting of  dysfunctional  myocardium due to  significant  coronary
artery disease is a key issue in making clinical decisions with respect to revascularization
procedures.  In  this  respect,  stress  myocardial  perfusion SPECT has  been extensively  in‐
vestigated. The hallmarks of myocardial viability supplied by a stenosed or occluded cor‐
onary artery are the perfusion defect with thallium redistribution on stress-redistribution
or  rest-redistribution  images,  fill-in  of  thallium,  setamibi,  and  tetrofosmin  after  reinjec‐
tion, or significant uptake on resting or reinjection images (usually more than 50-60% up‐
take  of  normal  area).  However,  the  ability  of  perfusion  tracers  to  differentiate  viable
from non-viable myocardium is not completely satisfactory as evidenced by recent viabil‐
ity studies using perfusion tracers [82-84]. In terms of the hallmark of viability in BMIPP
imaging, there are several  substantial  evidences that discordant BMIPP uptake less than
perfusion  tracers  is  a  marker  of  viability;  1)  as  previously  described,  such  mismatch  is
associated  with  ischemic  myocardium  as  evidenced  by  stress  perfusion  studies,  2)  in‐
creased FDG uptake was observed in areas with discordant BMIPP uptake less than thal‐
lium  and  higher  oxidative  metabolism  by11C-acetate  PET  was  observed  in  mismatched
area  than the  area  with  concordant  reduction of  BMIPP and perfusion [85],  3)  myocar‐
dial areas with BMIPP uptake less than sestamibi were more likely to have a positive re‐
sponse to dobutamine than areas with matched defect  [86,87],  4)  histologic  examination
in  patients  with  bypass  surgery  demonstrated  that  BMIPP  uptake  reduction  against  %
fibrosis looked biphasic, with steep reduction of BMIPP uptake within 20% of fibrosis, al‐
though,  thallium  uptake  reduction  correlated  linearly  to  %  fibrosis,  implying  the  areas
with discordant BMIPP uptake less than thallium had less than 20% fibrosis [88].
Functional recovery after revascularization has been investigated in relation to BMIPP up‐
take abnormality in patients with chronic coronary artery disease. Discordant BMIPP uptake
less than thallium could predict functional recovery after revascularization more precisely
than exercise-reinjection thallium study. In addition, the extent of discordance were a good
predictor of global ejection fraction improvement after revascularization [89]. Similarly, area
with discordant BMIPP uptake less than sestamibi measured by quantitative analysis was
highly predictive of improvement of ejection fraction, wall motion and free fatty acid utiliza‐
tion after revascularization [87]. Interestingly, the comparison of FDG, BMIPP, and sestami‐
bi uptake in patients with old myocardial infarction and stable ischemic regional wall
motion abnormalities demonstrated that extent of discordant BMIPP uptake less than FDG
uptake before revascularization highly correlated with ejection fraction improvement after
revascularization (r = 0.74) and also the extent of discordant BMIPP uptake less than sesta‐
mibi correlated significantly with ejection fraction improvement (r = 0.50). However, no sig‐
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nificant correlation was observed between the area with discordant FDG uptake more than
sestamib and ejection fraction recovery [90]. The results are quite intuitive because, in ische‐
mic and viable myocardium, substrate shift from fatty acid to glucose would take place,
hence, mismatch of FDG and BMIPP uptake should be prominent but mismatch between
BMIPP and sestamibi might be modest. These data suggest that discordant BMIPP uptake
less than perfusion may represent reversible ischemic myocardial injury or hibernating my‐
ocardium and that the regional and global dysfunction will improve after revascularization
in patients with chronic stable coronary artery disease. Metabolic stunning is also a good
marker of functional recovery. In acute myocardial infarction with emergency revasculariza‐
tion, BMIPP and tetrofosmin mismatch around 1 week after the revascularization predicted
recovery of ejection fraction and wall motion 3 month later [91,92].
5.6. Risk stratification and prediction of the prognosis
Assessment of prognostic value of BMIPP imaging over perfusion tracers in patients with
coronary artery disease is a matter of clinical importance. The initial study for the assess‐
ment of prognostic implications of BMIPP imaging was conducted in 50 consecutive pa‐
tients with myocardial infarction with a mean follow up period of 23 months [93]. During
the follow-up period, 9 patients had cardiac events; 8 of the 9 patients with cardiac events
showed discordant BMIPP uptake less than reinjection thallium, whereas only 20 of 41 pa‐
tients without cardiac events showed such mismatch. When all the clinical and radionuclide
variables were analyzed by Cox regression analysis, presence of discordant BMIPP uptake
was the best, and an independent, predictor of future cardiac events followed by the num‐
ber of coronary artery stenosis. BMIPP and thallium imaging performed within 1 month of
acute myocardial infarction demonstrated that impaired BMIPP uptake and mismatched
BMIPP uptake less than thallium are related to a high probability of fatal and non-fatal car‐
diac events [94] and the defect score of BMIPP and mismatched BMIPP uptake less than
thallium provided incremental predictive value for future cardiac events [95,96].
In the patients with chronic stage of myocardial infarction, clinical value of BMIPP imaging
for predicting prognosis is also demonstrated. BMIPP imaging performed before revascula‐
rization in 76 patients with chronic stable ischemia (including 61 patients with myocardial
infarction after at least 3 month of onset) with left ventricular dysfunction has been analyzed
[97]. Patients with large amount of discordant BMIPP uptake less than thallium demonstrat‐
ed greater ejection fraction improvement after revascularization and, interestingly, showed
significantly better event free survival than patients with small amount or no perfusion and
metabolic mismatch. These data indicate that patients with significant amount of discordant
BMIPP uptake less than thallium may benefit from revascularization.
In chronic coronary artery disease without old myocardial infarction, value of BMIPP imag‐
ing for risk stratification has been also demonstrated. In 270 patients, BMIPP defect score
was analyzed with respect to cardiac event during a median follow-up of 3.9 years [98]. Ka‐
plan-Meier survival estimates revealed that patients with a summed BMIPP defect score
lower than 5 showed a better prognosis than the patients with more defect of BMIPP (a hard
event-free survival rate at 3 years: 98% vs 93% (P = 0.03), all event-free survival rate at 3
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years: 92% vs 80% (P = 0.0003), respectively). More importantly, BMIPP was able to select a
high-risk subgroup among patients with diabetes mellitus as well as non-diabetic patients,
with 41% event rate in diabetic patients with BMIPP defect score 5 or more but only 4%
event rate in non-diabetic patients with BMIPP defect score lower than 5.
One of the strength of BMIPP imaging in daily clinical use is its simplicity since it offers
metabolic information without stress procedure. It is a matter of great interest whether rest‐
ing BMIPP imaging offers complementary or additional prognostic information to that pro‐
vided conventional stress perfusion imaging. One hundred and sity-seven consecutive
patients with angina pectoris but without prior myocardial infarction who had undergone
both BMIPP and stress thallium imaging were followed up for 48 months [99]. For overall
cardiac events (5 hard and 29 soft events), multivariate Cox’s analysis revealed that reduced
BMIPP uptake, stress perfusion score, diabetes, and left ventricular ejection fraction were
the significant predictors. No hard event was observed with normal BMIPP uptake, whereas
2 patients with nearly normal stress perfusion with impaired BMIPP uptake had a hard
event. The authors concluded that resting BMIPP imaging may provide significant prognos‐
tic information independent of stress myocardial perfusion imaging.
Recently meta-analysis on the prognostic value of BMIPP imaging in acute coronary syn‐
drome,  acute  myocardial  infarction,  and  stable  coronary  artery  disease  was  reported
[100].  In 3  studies  involving 541 patients  with suspected acute coronary syndrome who
were excluded for  acute  myocardial  infarction,  an abnormal  finding on BMIPP imaging
significantly  associated  with  future  hard  cardiac  events,  defined  as  cardiac  death  and
non-fatal  myocardial  infarction.  The negative predictive value of BMIPP imaging for fu‐
ture hard and soft events were 98.9% and 92.3% over 3.5 years, respectively. In 6 studies
which comprised 607 patients  with acute myocardial  infarction,  larger  defect  on BMIPP
imaging  was  significantly  associated  with  cardiac  death  and  hard  events  with  relative
risk  of  2.81  and  3.87,  respectively.  Two studies  included  166  patients  with  stable  coro‐
nary artery disease who underwent elective revascularization. Both studies evaluated the
prognostic value of mismatched BMIPP uptake less than perfusion, and showed contrast‐
ing  results  depending on the  timing of  BMIPP imaging to  relative  to  revascularization.
The  presence  of  mismatched  myocardium  before  revascularization,  which  suggested  a
jeopardized but viable myocardium, is  associated with fewer events  if  patients  undergo
successful  revascularization.  However,  the mismatch occurs after  revascularization,  indi‐
cating residual ischemia, the more hard events occur.
5.7. Chronic kidney disease
In chronic kidney disease (CKD), cardiovascular disease accounts for most of the morbid‐
ity  and  mortality  in  both  pre-dialysis  and  after  the  onset  of  end  stage  renal  disease.
Stress  myocardial  perfusion imaging has  become increasingly  recognized as  a  powerful
prognostic  tool  for  cardiovascular  outcomes  in  patents  with  known  or  suspected  coro‐
nary artery disease.  Abnormal stress myocardial  perfusion scan is  more common in pa‐
tients  with  CKD  and  stress  perfusion  imaging  is  confirmed  as  a  powerful  tool  for
predicting outcomes across entire spectrum of renal dysfunction. At the same time, pres‐
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ence of CKD itself  added prognostic value to perfusion imaging [101].  While stress per‐
fusion imaging is valuable method to assess coronary artery disease, stress test may not
be suitable for substantial number of CKD patients, especially in end stage renal disease.
Because  an  inability  to  exercise  enough due  to  multiple  comorbidity  including  obesity,
arthritis,  and deconditioning etc,  and suboptimal vasodilator stress testing due to an in‐
complete  vasodilator  response  due  to  endothelial  dysfunction.  In  this  context,  BMIPP
imaging can be performed safely and effectively at rest to detect metabolic alteration due
to ischemia without stress testing.
In addition to the high prevalence of coronary artery disease in patients with CKD, several
sequelae of renal failure also contribute to left ventricular metabolic remodeling, so-called
uremic cardiomyopathy. In this condition, myocyte capillary mismatch, with diminished
vascular supply relative to the number and volume of functioning myocytes is observed
[102,103]. These epicardial and microvascular disorder should induce ischemia when car‐
diac demand increases. For the detection of coronary artery disease in asymptomatic pa‐
tients undergoing hemodialysis, dual isotope SPECT with thallium and BMIPP was
investigated [104]. Significant coronary stenosis (>75%) was found in 72% of patients
(93/130). When a BMIPP summed score of 6 or more was defined as abnormal, sensitivity,
specificity, and accuracy for detecting coronary artery disease by BMIPP SPECT were 98.0%,
65.6%, and 90.0%, respectively. For the assessment of prognostic value of BMIPP in patients
with hemodialysis, 318 asymptomatic patients without prior myocardial infarction under‐
went dual isotope SPECT with thallium and BMIPP [105]. During a mean follow up period
of 3.6 ± 1.0 years, 50 died of cardiac event. Kaplan-Meier analysis showed that the cardiac
death-free survival rates at 3 years were 61% and 98% in patients with BMIPP summed
scores of >12 and <12, respectively. When the cutoff value of BMIPP–Tl mismatch score, a
marker of ischemia, was determined to be 7, the sensitivity and specificity of BMIPP–Tl mis‐
match for predicting cardiac death were 86% and 88%, respectively. Kaplan-Meier survival
estimates revealed that the event-free rates of cardiac death at 3 years were 53% in patients
with BMIPP–Tl mismatch of > 7, whereas 96% in patients with BMIPP–Tl mismatch < 7.
These finding suggested that significantly impaired myocardial fatty acid metabolism de‐
tected by BMIPP SPECT might predict the occurrence of cardiac death in asymptomatic he‐
modialysis patients. In addition, in patients with hemodialysis and complete coronary
revascularization, BMIPP imaging abnormality and BMIPP thallium mismatch can also pre‐
dict cardiac death [106]. Further more, prospectively enrolled 155 patients receiving hemo‐
dialysis after angiography had confirmed the absence of obstructive coronary lesions were
examined by BMIPP SPECT [107]. During a mean follow-up of 5.1 years, 42 patients died of
cardiac events. Stepwise Cox hazard analysis demonstrated that cardiac death asscociated
with reduced BMIPP uptake and increased insulin resistance. Thus, impaired myocardial
fatty acid metabolism and insulin resistance may be associated with cardiac death among
hemodialysis patients without obstructive coronary artery disease.
Accordingly, in patients with high risk CKD, BMIPP imaging at rest is highly valuable in
terms of the assessment of the myocardial metabolic abnormality, stratifying the patient’s
risk, and predicting cardiac death.
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6. Summary and conclusions
In normal condition approximately two-thirds or more of the total energy produced by my‐
ocardium is derived from fatty acid oxidation and myocardial substrates may change signif‐
icantly in various pathological conditions such as ischemia. Accordingly, many fatty acid
tracers for SPECT imaging have been introduced. Until now, 123I-BMIPP, one of the methyl
branched fatty acid analogues, is the only approved fatty acid tracer for daily clinical use.
The concept of BMIPP imaging is metabolic trapping, like FDG, by inhibiting β-oxidation by
introducing methyl branching at β-carbon position. Myocardial BMIPP uptake more likely
reflects activation of BMIPP into BMIPP-CoA with consumption of ATP, thus the uptake in‐
directly reflects cellular ATP production by fatty acid metabolism. Under the condition of
ischemia, the reduction of BMIPP uptake is observed by reflecting the reduction of ATP pro‐
duction due to depressed oxidative fatty acid metabolism and substrate shift from fatty
acids to glucose. Reduced uptake of BMIPP at rest is often observed in ischemic myocardi‐
um independent of the uptake of perfusion tracers, that is, discordant or mismatched BMIPP
uptake less than perfusion tracers. Through comparison with perfusion, BMIPP image can
detect previous myocardial ischemia as an ischemic memory imaging (stunned myocardium
or status of metabolic stunning) and viable but chronically dysfunctional myocardium (hi‐
bernating myocardium or status of metabolic remodeling). In addition, BMIPP image may
offer incremental prognostic information in ischemic heart diseases. Through the basic and
clinical studies, it has become clear that BMIPP imaging has a high potential utility in the
entire spectrum of ischemic heart diseases in evaluating the patients with acute chest pain,
acute myocardial infarction, unstable angina pectoris, chronic stable coronary artery diseas‐
es, in terms of diagnosis, risk stratification, and also for the prediction of prognosis.
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